DEPO - PRED 40 mg, a medication belongs to the class of corticosteroid with anti-inflammatory properties. It is primarily used to treat various inflammatory conditions and autoimmune diseases.

DEPO - PRED 40 mg is highly effective in reducing redness and swelling, as well as relieving pain and irritation caused by many inflammatory conditions.

DEPO - PRED 40 mg can be administered via intramuscular injection or directly into the joint for localized treatment.

Each 1 mL of DEPO - PRED 40 mg ampoules contains 40 mg Methylprednisolone acetate

A. For Intramuscular Administration:

Allergic States:

DEPO-PRED 40 mg is indicated for the management of severe, incapacitating allergic conditions unresponsive to adequate trials of conventional treatments, including bronchial asthma, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, and transfusion reactions.

Dermatologic Diseases:

 DEPO-PRED 40 mg is used for conditions such as bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, and Stevens-Johnson syndrome.

Endocrine Disorders:

DEPO-PRED 40 mg is effective in the treatment of primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, and hypercalcemia associated with malignancy.

Gastrointestinal Diseases:

DEPO-PRED 40 mg is indicated to assist patients in overcoming critical phases of the disease in regional enteritis (Crohn’s disease) and ulcerative colitis.

Hematologic Disorders:

DEPO-PRED 40 mg is used in cases of acquired (autoimmune) hemolytic anemia, pure red cell aplasia, and select cases of secondary thrombocytopenia.

Neoplastic Diseases:

DEPO-PRED 40 mg is used for palliative management in leukemias and lymphomas.

Nervous System:

DEPO-PRED 40 mg is effective in the treatment of acute exacerbations of multiple sclerosis and cerebral edema associated with primary or metastatic brain tumors.

Ophthalmic Diseases:

DEPO-PRED 40 mg is indicated for temporal arteritis and ocular inflammatory conditions unresponsive to topical corticosteroids.

Renal Diseases:

DEPO-PRED 40 mg is used to induce diuresis of proteinuria in idiopathic nephrotic syndrome or nephrotic syndrome or that due to lupus erythematosus.

Respiratory Diseases:

DEPO-PRED 40 mg is indicated for fulminating or disseminated pulmonary tuberculosis when used in conjunction with appropriate anti-tuberculous therapy, idiopathic eosinophilic pneumonias, and symptomatic sarcoidosis.

Rheumatic Disorders:

DEPO-PRED 40 mg is used as adjunctive therapy for short-term administration in acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, and systemic lupus erythematosus.

DEPO-PRED 40 mg is effective in the following conditions:

Trichinosis with neurological or myocardial involvement

Tuberculous meningitis with subarachnoid block or impending block when used in combination with appropriate antituberculous chemotherapy

B. For Intra-articular or Soft Tissue Administration:

DEPO-PRED 40 mg is indicated as adjunctive therapy for short-term administration (to assist the patient in overcoming an acute episode or exacerbation) in acute gouty arthritis, rheumatoid arthritis, and synovitis of osteoarthritis.

Children:

DEPO-PRED 40 mg should be limited to the shortest possible time.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking DEPO - PRED 40 mg.

Infants born to mothers who have received substantial doses of DEPO - PRED 40 mg during pregnancy should be carefully observed for signs of hypoadrenalism.

Pregnancy Category: C.

DEPO - PRED 40 mg should not be used whilst breastfeeding because of small amounts DEPO - PRED 40 mg appear in breast milk, which may lead to growth Suppression, affect the production of endogenous corticosteroids, and cause other side effects.

The initial dosage of DEPO - PRED 40 mg vary from 4 mg to 120 mg, depending on the specific disease being treated.

Adrenogenital Syndrome: The recommended dose is one ampoule of DEPO - PRED 40 mg (40 mg) every two weeks, which is usually sufficient.

Rheumatoid Arthritis: The recommended maintenance dose for patients with rheumatoid arthritis is a weekly intramuscular injection ranging from 40 mg to 120 mg.

Dermatologic Lesions: The recommended dose for patients with dermatologic lesions responsive to systemic corticosteroid therapy ranges from one ampoule (40 mg) to three ampoules (120 mg), administered intramuscularly at intervals of one to four weeks.

Seborrheic Dermatitis: The recommended weekly dose is two ampoules (80 mg), which is usually sufficient to control the condition. In cases of chronic contact dermatitis, repeated injections at intervals of 5 to 10 days may be necessary.

Bronchial Asthma and Allergic Rhinitis: Patients with asthma may require successive doses of DEPO - PRED 40 mg, ranging from two ampoules (80 mg) to three ampoules (120 mg).

Acute Exacerbations of Multiple Sclerosis: For the treatment of acute exacerbations of multiple sclerosis, daily doses of DEPO - PRED 40 mg up to four ampoules (160 mg) are administered for one week, followed by a dose of 64 mg every other day for one month.

Pediatric Patients: The initial dosage of DEPO - PRED 40 mg varies depending on the specific condition being treated. The range of initial doses is 0.11 mg to 1.6 mg/kg/day.